Your browser is no longer supported. Please, upgrade your browser.
BMY Bristol-Myers Squibb Company daily Stock Chart
Bristol-Myers Squibb Company
IndexS&P 500 P/E14.98 EPS (ttm)3.04 Insider Own0.10% Shs Outstand1.63B Perf Week-1.24%
Market Cap74.37B Forward P/E10.27 EPS next Y4.43 Insider Trans0.00% Shs Float1.63B Perf Month-7.46%
Income4.98B PEG1.87 EPS next Q1.08 Inst Own75.50% Short Float4.03% Perf Quarter-8.23%
Sales22.56B P/S3.30 EPS this Y28.70% Inst Trans0.07% Short Ratio3.50 Perf Half Y-21.29%
Book/sh8.59 P/B5.30 EPS next Y5.80% ROA14.60% Target Price57.80 Perf Year-12.96%
Cash/sh5.44 P/C8.37 EPS next 5Y7.99% ROE37.30% 52W Range44.30 - 63.69 Perf YTD-12.43%
Dividend1.64 P/FCF31.30 EPS past 5Y14.50% ROI25.40% 52W High-28.53% Beta0.78
Dividend %3.60% Quick Ratio1.50 Sales past 5Y6.60% Gross Margin71.50% 52W Low2.75% ATR0.93
Employees23300 Current Ratio1.60 Sales Q/Q9.60% Oper. Margin28.30% RSI (14)33.26 Volatility2.14% 1.89%
OptionableYes Debt/Eq0.52 EPS Q/Q105.30% Profit Margin21.80% Rel Volume1.26 Prev Close45.80
ShortableYes LT Debt/Eq0.40 EarningsApr 25 BMO Payout53.10% Avg Volume18.80M Price45.52
Recom2.30 SMA20-3.05% SMA50-7.76% SMA200-15.43% Volume23,603,520 Change-0.61%
Jan-15-19Upgrade Societe Generale Sell → Buy
Oct-22-18Downgrade Citigroup Buy → Neutral
Oct-09-18Resumed Guggenheim Neutral
Aug-08-18Upgrade Atlantic Equities Underweight → Neutral
Apr-17-18Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-12-18Reiterated Citigroup Buy $78 → $70
Mar-20-18Reiterated JP Morgan Overweight $70 → $75
Feb-15-18Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-30-17Upgrade SunTrust Hold → Buy
Oct-16-17Downgrade Jefferies Buy → Hold
Sep-12-17Downgrade Hilliard Lyons Long-term Buy → Neutral
Dec-19-16Upgrade Jefferies Hold → Buy
Oct-28-16Reiterated Deutsche Bank Hold $59 → $52
Sep-09-16Reiterated Barclays Equal Weight $75 → $65
Aug-11-16Downgrade Berenberg Buy → Hold
Aug-08-16Reiterated Deutsche Bank Hold $68 → $62
Aug-08-16Downgrade Credit Suisse Outperform → Neutral $63
Aug-05-16Downgrade Morgan Stanley Overweight → Equal-Weight
May-23-16Initiated Hilliard Lyons Neutral
Apr-29-16Reiterated UBS Buy $73 → $80
Apr-20-19 05:00PM  How Marijuana Legalization Affected OrganiGram and Aphria's Latest Results Motley Fool
08:00AM  3 Cancer Treatment Stocks to Buy in April Motley Fool
Apr-19-19 11:02AM  5 Top Healthcare Stocks to Buy in 2019 Motley Fool
Apr-18-19 10:33AM  Bristol-Myers Squibb (BMY) Reports Next Week: Wall Street Expects Earnings Growth Zacks
Apr-17-19 12:11PM  Bristol-Myers Squibb Company -- Moody's assigns A2 to Bristol-Myers's exchange notes; under review for downgrade Moody's
10:24AM  Bristol-Myers Squibb Company (NYSE:BMY): Immense Growth Potential? Simply Wall St.
08:18AM  Bristol-Myers Squibb Company Announces Commencement of Exchange Offers and Consent Solicitations for Celgene Notes Business Wire
07:48AM  Biotech Stock Roundup: GILD Collaborates on NASH, FCSC Surges on Deal Zacks
Apr-16-19 07:00PM  Bill Nygren Buys Constellation, S&P Global, Sells 5 in 1st Quarter
05:45PM  Bristol-Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know Zacks
10:54AM  Watch CNBC's exclusive interview with Starboard Value CEO Jeff Smith CNBC Videos
06:00AM  Why Celgene Shareholders Should Hold On to Their Bristol-Myers Squibb Stock Once the Acquisition Closes Motley Fool
Apr-15-19 06:56PM  52-Week Company Lows
01:53PM  Bristol-Myers' Shareholders Vote for Celgene Acquisition Zacks
09:57AM  Clovis Stalls Mid-Stage Rubraca Study for Bladder Cancer Zacks
Apr-14-19 12:15PM  Stocks That Fell to 3-Year Lows in the Week of April 12
Apr-12-19 06:56PM  Bristol-Myers CEO: We're 'one step closer to creating that great company' with Celgene CNBC Videos
06:50PM  'One step closer to creating that great company' with Celgene, says Bristol-Myers CEO CNBC Videos
06:32PM  Bristol-Myers CEO: We're 'one step closer to creating that great company' with Celgene CNBC
01:14PM  Bristol-Myers says shareholders vote to approve Celgene takeover Reuters
11:11AM  Bristol-Myers Squibb Shareholders Approve Celgene Tie-Up
10:48AM  Bristol-Myers Squibb Shareholders Approve Celgene Acquisition Business Wire
10:30AM  Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal Zacks
12:28AM  Bristol-Myers shareholders approve $90bn Celgene takeover Financial Times
Apr-11-19 05:43PM  6 Poorly Performing Stocks in Gurus' Portfolios
01:16PM  Bulls bet on one energy name. Plus: where Bristol-Myers may be heading CNBC Videos
09:53AM  Seattle Genetics' Adcetris Progresses Well Amid Competition Zacks
08:15AM  BMY Stock Looks Really Appetizing as the Celgene Merger Approaches InvestorPlace
06:59AM  Bristol-Myers Squibb Receives 2019 ENERGY STAR® Partner of the Year Sustained Excellence Award Business Wire
06:01AM  Bull of the Day: Centene (CNC) Zacks
Apr-10-19 03:24PM  Here's what to expect from the stock market next month Investopedia
11:11AM  Is AstraZeneca Stock Worth Buying Before Earnings? InvestorPlace
09:29AM  Bristol-Myers Squibb, JPMorgan Chase, and Other Dividend-Paying Stocks That Could Beat the Market
06:00AM  Starboard eclipses Elliott as most prolific activist hedge fund Financial Times
Apr-09-19 05:45PM  Bristol-Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know Zacks
Apr-08-19 06:11PM  Celgene & Acceleron Submit BLA for Luspatercept to the FDA Zacks
10:10AM  Why the Earnings Surprise Streak Could Continue for Bristol-Myers (BMY) Zacks
07:33AM  9 Companies That May Be on Warren Buffett's Takeover List Investopedia
06:52AM  3 Big Stock Charts for Monday: Bristol-Myers Squibb, Centurylink and Campbell Soup Company InvestorPlace
Apr-05-19 10:03PM  Exelixis (EXEL) Rallies 22.4% YTD: What to Expect Ahead? Zacks
05:29PM  Bill Nygren's 1st Quarter Oakmark Fund Commentary
10:20AM  Pharma Stock Roundup: NVS Inks Immunology Deal, PFE, TEVA Get Drug Approvals in EU Zacks
08:00AM  Health Day Checkup of Medical ETFs: 5 Top Picks Zacks
Apr-03-19 07:52PM  Activist Keith Meister Says This Years Market Rally and Last Decembers Sell-Off Made Us Break Even Insider Monkey
05:45PM  Bristol-Myers Squibb (BMY) Gains But Lags Market: What You Should Know Zacks
02:18PM  Is Celgene Stock Still Worth Holding Onto in the Long Run? InvestorPlace
10:22AM  Clovis Posts Data on Rubraca Study for Pancreatic Cancer Zacks
Apr-02-19 05:08PM  Why Celgene's Shares Soared 13.5% in March Motley Fool
01:00PM  Bristol-Myers Squibb Announces Long-Term Survival Results from Pooled Analyses of Opdivo (nivolumab) in Previously-Treated Non-Small Cell Lung Cancer Patients Business Wire
Apr-01-19 04:24PM  Celgene Gets Positive CHMP Nod for Revlimid Label Expansion Zacks
10:34AM  Bristol-Myers' (BMY) Acquisition of Celgene Looks Certain Zacks
10:15AM  Bristol-Myers Squibb/Celgene deal opponent backs off its opposition American City Business Journals
09:56AM  Celgene stock downgraded to neutral at UBS MarketWatch
09:21AM  The Zacks Analyst Blog Highlights: Phillip Morris, Bristol-Myers, Walgreens, Sirius and Total System Zacks
08:53AM  3 Big Pharma Stocks to Add to Your Portfolio This April Zacks
Mar-31-19 11:02AM  Bristol-Myers Gets ISS Support for Celgene Takeover; Starboard Drops Opposition
Mar-30-19 10:09AM  Income Investors Should Know The Bristol-Myers Squibb Company (NYSE:BMY) Ex-Dividend Date Simply Wall St.
Mar-29-19 05:48PM  Are the health care stocks flat lining? Here are the beaten down names traders are still buying CNBC Videos
05:03PM  Stock Market Today: Lyft Goes Public Motley Fool
04:31PM  Dow rallies more than 200 points as S&P 500 logs its best quarterly advance since 2009 MarketWatch
03:53PM  5 Top Stock Trades for Monday: Lyft, RH, Celgene, Wells Fargo InvestorPlace
01:33PM  Bristol-Myers Squibb Issues Statement on Celgenes Settlement with Alvogen on Revlimid® Patent Litigation Business Wire
01:30PM  Top Research Reports for Phillip Morris, Bristol-Myers & Walgreens Boots Zacks
01:12PM  Starboard abandons campaign to scuttle Bristol-Myers-Celgene deal Reuters
12:49PM  Proxy advisers ISS, Glass Lewis back Bristol-Myers takeover of Celgene Reuters
12:48PM  Starboard no longer urging investors to vote against Bristol-Celgene deal Reuters
12:40PM  Celgene's stock surges, after Starboard withdraws proxy fight of Bristol-Myers buyout deal MarketWatch
12:38PM  Starboard Ends Proxy Fight at Bristol-Myers Ahead of Vote Bloomberg
12:30PM  Celgene Stock Breaks Out As Bristol Grabs Key Merger Endorsement Investor's Business Daily
12:02PM  Starboard Issues Statement on Bristol-Myers PR Newswire
11:13AM  Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Bristol-Myers Squibb Shareholders Vote FOR Proposed Merger with Celgene Business Wire
10:53AM  Celgene Stock Is Surging After ISS Backs Bristol Deal
09:35AM  Proxy advisor ISS backs Bristol takeover of Celgene Reuters
07:00AM  Bristol-Myers/Celgene Deal Is About to Face a Crucial Test
Mar-28-19 10:18PM  Bristol-Myers wins major proxy advisor support for $90bn Celgene buy Financial Times
04:34PM  Is Biogen a Beat-Up Bargain? And Is Bristol-Myers' Mega-Merger on the Rocks? Motley Fool
10:07AM  Starboard Mails Letter to All Bristol-Myers Squibb Shareholders PR Newswire
09:41AM  Jefferies' revenue hurt by U.S. govt. shutdown and weak markets in Dec. Reuters
Mar-27-19 02:47PM  5 Cancer-Fighting Stocks to Boost Portfolio Gains Zacks
10:29AM  J&J Files sBLA for Darzalex in Expanded Myeloma Patient Group Zacks
Mar-26-19 10:05PM  Is Bristol Myers Squibb Company (BMY) A Good Stock To Buy? Insider Monkey
05:45PM  Bristol-Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know Zacks
05:32PM  Amid talk of buyout, Peninsula biotech zeroes in on its blood-thinner antidote American City Business Journals
05:15PM  Celgene (CELG) Submits NDA for MS Drug to FDA for Review Zacks
03:41PM  Celgene Stock Is Up Because Its FDA Application Is a Good Sign, Analyst Says
02:05PM  FTC focuses on psoriasis franchise for Bristol-Celgene deal review Reuters
11:59AM  FTC focuses on psoriasis franchise for Bristol-Celgene deal review Reuters
08:29AM  FTC seeks more information to review Bristol-Celgene's $74 bln planned merger Reuters
07:32AM  Bristol-Myers Gets FTC Request for More Information on $74 Billion Celgene Deal
07:23AM  Jim Cramer Gives His Opinion On Bristol-Myers Squibb, Moderna And More Benzinga
Mar-25-19 11:13AM  J&J Files Application for Darzalex Label Expansion in Europe Zacks
07:40AM  Report: Developing Opportunities within Bristol-Myers Squibb, AutoNation, FirstEnergy, Charles River Laboratories International, Yum! Brands, and AGNC Investment Future Expectations, Projections Moving into 2019 GlobeNewswire
06:59AM  Bristol-Myers Squibb Board of Directors Sends Letter to Shareholders Highlighting the Compelling Strategic and Financial Rationale of the Celgene Transaction; Company Provides Additional Investor Materials Business Wire
Mar-24-19 01:00PM  Is It Safe to Buy Biogen Stock Right Now? InvestorPlace
Mar-22-19 09:15AM  Why Bristol-Myers Squibb (BMY) is a Great Dividend Stock Right Now Zacks
Mar-21-19 10:10AM  Merck's Keytruda Picks Up Pace in Thriving Anti-PD-L1 Market Zacks
10:03AM  Bristol-Myers' Celgene Buyout Still Uncertain Amid Opposition Zacks
07:30AM  Proxy Advisors Could Tilt the Scales in the Bristol-Celgene Deal. Watch for Their Calls Next Week.
Mar-20-19 05:45PM  Bristol-Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know Zacks
11:30AM  Pfizer/Merck KGaA End Bavencio+Talzenna Ovarian Cancer Study Zacks
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis. It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, the company offers Reyataz, a protease inhibitor for the treatment of human immunodeficiency virus (HIV) and Evotaz; Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. It has collaboration agreements with Nektar Therapeutics, Janssen Pharmaceuticals, Inc., and Biocartis Group NV. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerApr 03Option Exercise0.0011,594025,816Apr 05 04:32 PM
Elicker John ESVP, Public Affairs & IRMar 10Option Exercise0.0014,180092,626Mar 13 07:42 AM
BOERNER CHRISTOPHER S.EVP, Chief Commercial OfficerMar 10Option Exercise0.0015,707014,501Mar 13 07:41 AM
Dubow AdamChief Compliance & Ethics OffiMar 10Option Exercise0.003,735018,240Mar 13 07:41 AM
Caforio GiovanniChairman and CEOMar 10Option Exercise0.00173,4190422,683Mar 13 07:40 AM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0062,2550411,547Mar 13 07:39 AM
Biondi PaulSVP, Head of Strategy & BDMar 10Option Exercise0.008,61907,860Mar 13 07:39 AM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.0019,9250141,077Mar 13 07:38 AM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.0026,568063,652Mar 13 07:37 AM
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerMar 10Option Exercise0.005,864021,343Mar 13 07:36 AM
Santiago Karen MurphyControllerMar 10Option Exercise0.003,82506,850Mar 13 07:37 AM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0045,1700558,854Mar 13 07:35 AM
JUDGE ANN POWELLSVP, Global Human ResourcesMar 10Option Exercise0.0025,577081,508Mar 13 07:34 AM
Bancroft Charles AEVP & Chief Financial OfficerFeb 28Option Exercise17.5152,884925,999392,690Mar 04 04:42 PM
LEUNG SANDRAEVP, General CounselFeb 28Option Exercise17.51169,8932,974,826634,478Mar 04 04:42 PM
BOERNER CHRISTOPHER S.EVP, Chief Commercial OfficerFeb 02Option Exercise0.004,46504,465Feb 05 04:53 PM
Bancroft Charles AEVP & Chief Financial OfficerDec 02Option Exercise0.006,4010206,117Dec 04 04:31 PM
Biondi PaulSVP, Head of Strategy & BDOct 02Option Exercise0.005920592Oct 04 04:56 PM
Dubow AdamChief Compliance & Ethics OffiSep 03Option Exercise0.00797015,495Sep 05 04:49 PM
Santiago Karen MurphyControllerSep 01Option Exercise0.0064104,057Sep 05 04:49 PM
Gordon MurdoEVP, Chief Commercial OfficerAug 01Option Exercise0.001,510050,168Aug 03 05:05 PM
Biondi PaulSVP, Head of Strategy & BDJul 01Option Exercise0.001,46101,461Jul 03 09:24 PM
Caforio GiovanniChairman and CEOMay 05Option Exercise0.008,0400292,822May 08 05:05 PM
Paliwal Dinesh CDirectorApr 30Buy52.404,770249,9488,027May 02 04:05 PM